- Report
- September 2026
- 194 Pages
Global
From €3268EUR$3,545USD£2,729GBP
€3631EUR$3,939USD£3,032GBP
- Report
- September 2026
- 188 Pages
Global
From €3268EUR$3,545USD£2,729GBP
€3631EUR$3,939USD£3,032GBP
- Report
- September 2026
- 194 Pages
Global
From €3268EUR$3,545USD£2,729GBP
€3631EUR$3,939USD£3,032GBP
- Report
- September 2026
- 183 Pages
Global
From €3268EUR$3,545USD£2,729GBP
€3631EUR$3,939USD£3,032GBP
- Report
- September 2026
- 198 Pages
Global
From €3268EUR$3,545USD£2,729GBP
€3631EUR$3,939USD£3,032GBP
- Report
- September 2026
- 182 Pages
Global
From €3268EUR$3,545USD£2,729GBP
€3631EUR$3,939USD£3,032GBP
- Report
- January 2026
- 187 Pages
Global
From €3268EUR$3,545USD£2,729GBP
€3631EUR$3,939USD£3,032GBP
- Report
- November 2026
- 385 Pages
Global
From €5393EUR$5,850USD£4,503GBP
- Report
- July 2026
- 120 Pages
Global
From €4379EUR$4,750USD£3,656GBP
- Report
- July 2026
- 140 Pages
Global
From €4379EUR$4,750USD£3,656GBP
- Report
- July 2026
- 120 Pages
Global
From €4379EUR$4,750USD£3,656GBP
- Report
- August 2026
- 185 Pages
Global
From €4379EUR$4,750USD£3,656GBP
- Report
- May 2026
- 150 Pages
Global
From €3457EUR$3,750USD£2,886GBP
- Report
- May 2026
- 150 Pages
Global
From €3642EUR$3,950USD£3,040GBP
- Report
- May 2026
- 154 Pages
Global
From €3642EUR$3,950USD£3,040GBP
- Report
- May 2026
- 146 Pages
Global
From €3642EUR$3,950USD£3,040GBP
- Report
- May 2026
- 148 Pages
Global
From €3642EUR$3,950USD£3,040GBP
- Report
- May 2026
- 143 Pages
Global
From €3642EUR$3,950USD£3,040GBP
- Report
- August 2026
- 160 Pages
Global
From €3061EUR$3,320USD£2,555GBP
€3826EUR$4,150USD£3,194GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €8297EUR$9,000USD£6,927GBP

The Tumor Profiling market within the Diagnostics industry is a rapidly growing sector. It involves the use of advanced technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to analyze the genetic makeup of tumors. This helps to identify the specific mutations that are driving the tumor's growth, allowing for more targeted treatments. Tumor profiling can also be used to monitor the effectiveness of treatments and to detect recurrence of the tumor.
The market is driven by the increasing prevalence of cancer, the growing demand for personalized medicine, and the development of new technologies. Additionally, the increasing availability of genomic data and the development of artificial intelligence (AI) and machine learning (ML) are expected to further drive the market.
Some of the major companies in the Tumor Profiling market include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and Roche. Show Less Read more